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DEAR EDITOR,  
Actinic keratosis (AK) is caused by ultraviolet radiation exposure and is more likely to be 
subclinical than visible. AK can potentially progress to invasive squamous cell carcinoma 
(SCC).
1
 All stages of AK and sometimes, invasive SCC
2 
coexist in the “cancerization field” 
where further neoplastic changes can occur.
3
 The current clinical or histological based classi-
fication systems are time consuming and are restricted by the presence of multiple lesions.
4,5 
The Actinic Keratosis Area Severity Index (AKASI) score evaluates sun damaged skin in de-
fined regions of the head, estimating a grade of severity according to erythema, distribution 
and lesion thickness, along with the area affected. The head is divided into four areas and 
each region is given a weighting based on its approximate relative size as follows: scalp 40%; 
forehead 20%; left cheek, ear, chin and nose 20%; right cheek, ear, chin and nose 20%. For 
each region, the initial step is to estimate the percentage of the area that is affected by actinic 
damage, represented by a numerical value between 0 and 6. The three clinical signs of AK 
severity; distribution (none, isolated/scattered, clustered, clustered/confluent, all confluent), 
erythema (absent, slight, moderate, intense, very intense) and thickness (no palpability, just 
palpable, clearly palpable, thickened, very thickened) are assessed and scaled (0 – 4).6 An 
AKASI subscore is calculated for each of the four areas of the head by adding the area and 
severity scores, and multiplying the subtotal by the area coefficient. The subtotals together 
give a total AKASI score for the entire head. Total scores range from 0 (no AK / no actinic 
damage) to 18 (AK of the severest possible degree).
6 
In a pilot study of 30 consecutive patients, the reproducibility and accuracy of diagnosis with 
AKASI compared with Total Lesion Count (TLC), the current gold standard for AK severity 
reporting, was performed. Patients without previous skin cancer diagnosis and/or field and/or 
lesion treatments, on the area of evaluation were enrolled and examined by four dermatolo-
gists, blinded to colleagues’ diagnoses, following a consensus discussion of what lesions con-
stitute AKs.
7
  
Most patients were men (n=23), with a mean age of 77 years (range 63 – 87). Mean TLC re-
sults were 38.7 ±20.7 (0-94). The intra-class correlation coefficient (ICC) for intra-observer 
TLC and for each parameter was almost perfect (>80) but, when investigating the agreement 
between the observers according to TLC types, there was a lower correlation for AK type II 
compared to AK I and III. Type II lesions are discrete and are in part or totally covered by a 
scaly surface. Incorrectly classified Type II as Type III could be of particular importance for 
clinical trials, as most studies exclude Type III, suggesting that inclusion and exclusion crite-
ria could be much more subjective than previously thought.  
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Mean AKASI results were 7.1 ±2.5 (0-12.6). When considering the single AKASI score there 
was an almost perfect correlation for intra-observer and for each parameter (area score, 
thickness and distribution). AKASI thickness seemed easier to score than TLC, probably due 
to the different scoring methodologies. The presence of 4 different grades of thickness (none, 
just palpable, palpable, thick and very thick) could permit a better classification than a triple 
choice (non-palpable, palpable, very palpable). Interestingly, the classification of erythema 
presented the greatest range of scores. By definition, erythema in AKASI pertains to that 
within a sun-damaged field, and not due to telangiectasia, dermatitis or eczema, which can 
arise or co-exist in the same area, potentially confounding the observer. 
Inter-observer variability analysis of TLC and AKASI showed no significant differences be-
tween the 4 observers (P>0.05). However, the ICC was slightly lower for TLC among the ob-
servers than for AKASI (0.92, 95% confidence interval (CI), 0.86-0.95; vs 0.94, 95% CI, 
0.90-0.97, respectively). Disease severity was classified similarly by either method of evalua-
tion, as evidenced by the global AKASI and TLC scores correlation in a linear fashion 
(r=0.75; 95% CI, 0.66-0.82, p<0.00; Figure 1).  
According to Bland Altman analysis, the level of agreement (LoA) for both methodologies of 
classification by each observer was almost perfect, and as the differences within the mean 
and standard deviation were not clinically important, the two methods could be used inter-
changeably.  
In this pilot study, AKASI seems to be a potential alternative scoring system for TLC in both 
clinical and future clinical trial settings. Cut-off thresholds could help standardize patient 
comparisons and assist in tailoring and assessing individual treatments. Further validation in 
multicentre/multi-observer settings is required.  
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FIGURE LEGEND 
 
Figure 1. Correlation between the global AKASI scores and the global TLC scores for all 30 
patients by 4 independent blinded observers. 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
